research A COMPARISON OF INTRA-LESIONAL TRIAMINOLONE HEXA-CETONIDE AND TRIAMCINOLONE ACETONIDE IN ALOPECIA AREATA
Both steroids effectively promote hair growth for at least 9 months.
Search
for
Sort by
Research
750-780 / 1000+ resultsresearch Bexarotene gel: A new topical therapy for alopecia areata
Bexarotene gel shows promise as a new treatment for alopecia areata.
research The dual-action monophenolic antioxidant TS-13 accelerates hair coat restoration in a mouse model of chemotherapy-induced alopecia
TS-13 speeds up hair regrowth after chemotherapy.
research Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
research Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
Oral and topical tofacitinib can help regrow hair in people with severe alopecia areata.
research Azathioprine
A woman experienced hair loss, nail changes, bone marrow suppression, and low blood protein after taking azathioprine.
research Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment
Scalp cooling significantly reduces hair loss in chemotherapy patients.
research Non-Steroidal Modulation of the 5-Alpha Reductase Axis: A Dual Therapeutic Strategy for Prostatic Chemoprevention and Androgenetic Alopecia
LX-38 is a safer drug option for treating prostate issues and hair loss without hormonal side effects.
research Isoxazole 9 (ISX9), a small molecule targeting Axin, activates Wnt/β‐catenin signalling and promotes hair regrowth
Isoxazole 9 (ISX9) may help regrow hair by activating certain cell signals.
research Analysis of chemotherapy-induced peripheral neuropathy using the Japanese Adverse Drug Event Report database
Certain cancer drugs are strongly linked to nerve damage, requiring close monitoring and early treatment.
research Ivarmacitinib for the treatment of adults with severe alopecia areata: Results from a phase 3 trial
research 049 Investigating the immunomodulatory mechanism of dithranol in alopecia areata through blood-based in vitro studies
Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
research Annurca Apple Polyphenols Protect Murine Hair Follicles from Taxane Induced Dystrophy and Hijacks Polyunsaturated Fatty Acid Metabolism toward β-Oxidation
Annurca apple extract may protect mouse hair from damage by chemotherapy and could help treat hair loss without promoting cancer growth.
research Effets secondaires cutanéo-muqueux des nouvelles molécules anticancéreuses: Inhibiteurs de l'EGF-R, inhibiteurs de tyrosine kinase et stabilisateurs du fuseau mitotique
New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.
research Identification of xenobiotics interfering with 5 α -reductase (SRD5A2) activity
MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.
research Combined Corticosteroid and Minoxidil Therapy for Early Recovery in Radiation-Induced Alopecia: A Case Report
Combining corticosteroids and minoxidil can quickly regrow hair lost from radiation.
research Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
research Ameliorative effect of tranexamic acid on physiological skin aging and its sex difference in mice
Tranexamic acid reduces skin aging more in female mice.
research Hair Follicle–Derived Blood Vessels Vascularize Tumors in Skin and Are Inhibited by Doxorubicin
Doxorubicin can block blood vessels from hair follicles, reducing skin tumor growth.
research TOFACITINIB IN OVERLAPPING AUTOIMMUNE AND AUTOINFLAMMATORY DISORDERS: A CASE REPORT OF A DUAL GRAHAM-LITTLE-PICCARDI-LASSEUR SYNDROME AND HIDRADENITIS SUPPURATIVA
Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research 0282 Effect of systemic immunomodulators on incidence of alopecia areata: A retrospective cohort study
Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
research Inhibidor janus kinasa como opción terapéutica en alopecia areata. Reporte de caso
Janus kinase inhibitors may effectively treat severe alopecia areata unresponsive to other treatments.
research Investigação das atividades alelopática, fitotóxica e antioxidante de extratos e frações de Tridax procumbens L. (Asteraceae). e Ouratea spectabilis (mart. ex engl.) engl. (Ochnaceae)
Tridax procumbens and Ouratea spectabilis can affect other plants' growth and have antioxidant benefits.
research Betamethasone valerate/minoxidil/tretinoin
The combination of tretinoin, minoxidil, and betamethasone valerate may cause severe scalp inflammation.
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Fast clinical response with topical ruxolitinib in the management of non-segmental vitiligo detected by VISIA® analysis system
Topical ruxolitinib quickly improves non-segmental vitiligo.
research JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
research FOCAL HYPERTRICHOSIS DURING TOPICAL TACROLIMUS THERAPY FOR CHILDHOOD VITILIGO
An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.